Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...

Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...

Oculis (OCS) stock jumps as the FDA grants Breakthrough Therapy designation for its eye disease drug Privosegtor targeted at optic neuritis. Read more here.

ZUG, Switzerland, January 6, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ...

After five years, Nido Biosciences has reached the end of the road, closing its doors after its lead neurological disease candidate disappointed in a midstage study. Founded by 5AM Ventures’ 4:59 ...

If you're looking for an artsy aesthetic in your images, Lensbaby's Optic Swap system is a great place to start. From the Composer Pro II to the Sweet 50, these are the top housing and lens options we ...

LED bulbs come with big promises, like energy savings and lights that will last for years of use without burning out like old incandescents. Many of those promises are true, but we bet you've noticed ...

This roundup highlights recent FDA updates related to drug approvals and devices used by optometric eye care professionals.